Entrada Therapeutics Inc. (TRDA)
| Bid | 8.45 |
| Market Cap | 327.45M |
| Revenue (ttm) | 210.78M |
| Net Income (ttm) | 65.63M |
| EPS (ttm) | 1.68 |
| PE Ratio (ttm) | 5.18 |
| Forward PE | -2.65 |
| Analyst | Buy |
| Ask | 10 |
| Volume | 126,445 |
| Avg. Volume (20D) | 132,904 |
| Open | 8.96 |
| Previous Close | 8.71 |
| Day's Range | 8.71 - 9.26 |
| 52-Week Range | 7.10 - 21.79 |
| Beta | 0.03 |
About TRDA
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...
Analyst Forecast
According to 3 analyst ratings, the average rating for TRDA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 221.47% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Entrada Therapeutics: Cash-Rich Innovator With Asymmetric UpsideEntrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 milli...